Browse by category

Outcomes from Viking Therapeutics’ Phase 2 VENTURE clinical trial of VK2735 - a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors – reveal that after 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. The outcomes highlights the previously reported positive results from th

Viking Therapeutics has completed patient enrolment in its Phase 3 VANQUISH-1 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. The Phase 3 VANQUISH-1 study is a randomised, double-blind, placebo-controlled, multi-centre t

Viking Therapeutics has announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of...

Patients receiving weekly doses of Viking Therapeutics’ VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and...

Viking Therapeutics has completed patient enrolment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of...

Outcomes from Viking Therapeutics’ Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were...

Viking Therapeutics has initiated a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like...

Viking Therapeutics has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like...